You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Article info

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - other biologic treatment
SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Authors

Citation

Weinblatt M, Mease P, Mysler E, et al
SAT0244 A Phase Iib Study of the Efficacy and Safety of Subcutaneous Clazakizumab (ANTI-IL-6 Monoclonal Antibody) with or without Methotrexate in Adults with Moderate-To-Severe Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Annals of the Rheumatic Diseases 2014;73:680-681.

Publication history

  • First published June 10, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2014, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions